Pharmacutical Small Molecule Prefilled Syringes Market | Page 2

REPORT DESCRIPTION
Small Molecule Prefilled Syringes Market – Overview
The global small molecule prefilled syringes market was valued at US$ 13,749.4 million in 2016 and is
expected to witness a robust CAGR of 4.6% over the forecast period (2017–2025).
Manufacturers are focusing on capitalizing on patent losses to launch generic versions in the market. For
instance, in 2017, Mylan N.V. launched generic alternative to Copaxone 40 mg/ml for multiple sclerosis
patients in the U.S. Moreover, Mylan N.V. launched Brabio, first generic alternative to Copaxone 40
mg/ml, for multiple sclerosis patients in the U.K., in January 2018. Teva Pharmaceuticals enhanced
presence in Multiple Sclerosis segment through the introduction of three-times-a-week Copaxone 40
mg/mL product in the U.S in 2014. In 2015, Teva Pharmaceuticals launched Generic Lovenox in the U.S.
market. In 2016, Fresenius Kabi launched Ketorolac injection in its ready-to-administer prefilled glass
syringe. Sandoz announced the U.S. Food & Drug Administration approval and launch of Glatopa
(Glatiramer acetate) 40 mg/mL, in February 2018.